Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medlive Technology Co., Ltd. ( (HK:2192) ) has provided an update.
Medlive Technology Co., Ltd. has convened its annual general meeting for 15 May 2026 in Beijing, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividend. The meeting will also consider the re-election of three directors, the appointment of Deloitte Touche Tohmatsu as auditor, and authorizations for the board to repurchase up to 10% of the company’s share capital and to issue new shares within specified limits, measures that collectively refresh governance structures and give management additional flexibility over capital management and future financing.
If approved, the dividend and board reappointments would signal continuity in Medlive’s management and financial policy, which may reassure investors about the stability of its digital healthcare operations. The proposed share repurchase and general share issuance mandates are standard corporate tools in Hong Kong that could support capital structure optimization and potential growth initiatives, while also affecting future share supply and shareholder value depending on how actively the board uses these authorities.
More about Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd. is a Cayman Islands–incorporated company listed in Hong Kong and operates in the healthcare technology sector. The group provides digital medical services and related solutions, serving healthcare professionals and institutions in mainland China and other markets through online platforms and data-driven tools.
Average Trading Volume: 3,272,311
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.67B
For an in-depth examination of 2192 stock, go to TipRanks’ Overview page.